Evidence map›Paper›PMID 26579460›Full record

ReviewActa pharmaceutica Sinica. B2015

The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb.

Liqiang Wang, Rui Yang, Bochuan Yuan, Ying Liu, Chunsheng Liu

Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04487964 (Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine), which is not on this map. Cited by 225 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 2 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04487964 nacompletednot on this mapstarted 2020, after this paper: background citation

Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine

TypeinterventionalSponsorEgyptian Biomedical Research NetworkRan2020 to 2021Enrolled50ConditionsCOVID-19ArmsLicorice extract
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 2 syntheses or guidelines pooled it, 573 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Liqiang WangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China.
Rui YangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China.
Bochuan YuanSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China.
Ying LiuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China.
Chunsheng LiuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Licorice is a common herb which has been used in traditional Chinese medicine for centuries. More than 20 triterpenoids and nearly 300 flavonoids have been isolated from licorice. Recent studies have shown that these metabolites possess many pharmacological activities, such as antiviral, antimicrobial, anti-inflammatory, antitumor and other activities. This paper provides a summary of the antiviral and antimicrobial activities of licorice. The active components and the possible mechanisms for these activities are summarized in detail. This review will be helpful for the further studies of licorice for its potential therapeutic effects as an antiviral or an antimicrobial agent.

Indexed as

AntimicrobialAntiviralCCEC, cerebral capillary vessel endothelialCCL5, chemokine (C-C motif) ligand 5ChalconeCVA16, coxsackievirus A16CVB3, coxsackievirus B3CXCL10, chemokine, (C-X-C motif) ligand 10DGC, dehydroglyasperin CDHV, duck hepatitis virusEV71, enterovirus 71GA, 18β-glycyrrhetinic acidGATS, glycyrrhizic acid trisodium saltGLD, glabridinGL, glycyrrhizinGlycyrrhetinic acidGlycyrrhizinHBV, hepatitis B virusHCV, hepatitis C virusHIV, human immunodeficiency virusHMGB1, high-mobility-group box1HRSV, human respiratory syncytial virusHSV1, herpes simplex virus type 1HSV, herpes simplex virusIFN, interferonIL-6, interleukin-6ISL, isoliquiritigeninLCA, licochalcone ALCE, licochalcone ELicoriceLTG, liquiritigeninMgIG, magnesium isoglycyrrhizinateMRSA, methicillin-resistant Staphylococcus aureusMSSA, methicillin-sensitive Staphylococcus aureusPMN, polymorph nuclearPrV, pseudorabies virusTCM, traditional Chinese medicine

Identifiers

PMID26579460
PMCPMC4629407
OpenAlexW655885092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.